ClinicalTrials.gg
CompletedNCT01252628Updated May 16, 2018

Phase 1 and 2 Study of PX-866 and Cetuximab

A Phase 1/2 interventional study of PX-866 (SCCHN) and Cetuximab (SCCHN) in Incurable Metastatic Colorectal Carcinoma and Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, sponsored by Cascadian Therapeutics Inc.. Completed at 40 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.

Primary conditionColorectal NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cascadian Therapeutics Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
40th of 185
178 · median 60
Started
2010
with 11 others
Phase 1/2
20 of 187
6 open now
Registered
84th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 40th largest by enrollment of the 185 interventional ones that give a count, is one of 12 that started in 2010, is one of 20 in phase 1/2, and was the 84th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment. In the Phase 1 part of the study, the dose of PX-866 to be given in combination with cetuximab will be determined in patients with incurable metastatic CRC or incurable progressive, recurrent or metastatic SCCHN. The Phase 2 part of the study is a randomized evaluation of the antitumor activity and safety of PX-866 in combination with cetuximab versus cetuximab alone in patients with either incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or incurable progressive, recurrent or metastatic SCCHN (Group 2).

Read the detailed description

Phase 1 will determine the maximally tolerated or recommended dose of PX-866 to be given orally on Days 1-21 in combination with cetuximab 250 mg/m2 administered IV weekly on Days 1, 8, and 15 of a 21-day cycle. All patients will receive an initial loading dose of 400 mg/m2 cetuximab rather than 250 mg/m2 on Cycle 1 Day 1. Patients may receive premedication with an H1 antagonist per the cetuximab package insert. Up to 3 dose levels of PX-866 will be evaluated to determine the MTD/RD in cohorts of up to 6 patients using a standard 3+3 dose-escalation design. At least 6 patients will be treated at the MTD/RD. All patients in Phase 1 will be required to undergo PK assessments during Cycle 1 Week 3 to measure cetuximab levels. Exploratory PD assessments will include evaluation of changes in levels of fasting C-peptide as well as changes in EGFR and PI-3K signaling pathways in peripheral blood mononuclear cells (PBMC) and platelets. Additional optional evaluations will include changes in EGFR and PI-3K signaling in paired tumor biopsies provided before and after one cycle of treatment. All patients will be asked, but not required, to provide an archived tumor biopsy sample for evaluation for potential biomarkers of response to PX-866 and cetuximab.

Phase 2 is an open-label, randomized evaluation of the antitumor activity and safety of PX-866 administered orally or via PEG tube (if applicable) at the MTD/RD in combination with cetuximab, versus cetuximab alone in cetuximab-naïve patients with incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or patients with incurable progressive, recurrent or metastatic SCCHN (Group 2). Seventy two evaluable patients (36 patients per arm) will be evaluated per indication. Patients will be randomized 1:1 to receive PX-866 + cetuximab or cetuximab alone.

03

Conditions studied

  • Incurable Metastatic Colorectal Carcinoma
  • Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Browse trials for

Keywords

  • CRC
  • SCCHN
  • PX-866
  • Cetuximab
  • ERBITUX
  • Colon
  • Head and Neck
  • Colorectal cancer
  • Squamous cell carcinoma
  • PI-3K
  • PI3 kinase
  • PI3K
04

In context

Colorectal Neoplasms Reclassified

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's enrollment of 178 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Cascadian Therapeutics Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

First submitted before Cascadian Therapeutics Inc. became part of Pfizer.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years at time of consent
  • Use of a medically accepted form of from the time of consent to completion of all follow-up study visits
  • If female of , negative pregnancy test
  • Signed an
  • per (RECIST)
  • Documentation available for last prior systemic treatment including dates of treatment, best response to treatment, duration of best response, and reason for discontinuation of treatment
  • (ECOG) 0 or 1
  • Group 1: Patients with incurable CRC with a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens. Patients who have a history of intolerance of irinotecan based therapy or ineligibility to receive irinotecan are also eligible as long as they have received a prior oxaliplatin containing regimen.
  • Group 2: Patients with incurable SCCHN with a history of progression or recurrence following at least one prior platinum based chemotherapy or chemotherapy/radiation containing regimen. Patients who have a history of intolerance of platinum based therapy or history of ineligibility to receive a platinum based regimen are also eligible. SCCHN patients who received cetuximab as a radiosensitizer for locally advanced disease and completed treatment at least 6 months prior to start of study drug treatment are eligible
  • In the opinion of the clinical investigator, of greater than 3 months
  • Adequate hematologic function
  • Adequate hepatic function
  • Creatinine level ≤1.5 x
  • Serum magnesium ≥ LLN.

Exclusion criteria

Exclusion Criteria:

  • Has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures
  • Is breastfeeding
  • Treatment with any systemic chemotherapy, epidermal growth factor receptor (EGFR) inhibitor, radiation or experimental agent within 4 weeks of study drug dosing
  • Received prior cetuximab, except as defined in inclusion criteria
  • Previous treatment with a phosphatidylinositol 3-kinase (PI-3K) inhibitor
  • Known (HIV)
  • Poorly controlled diabetes mellitus (IFCC- ≥ 53 mmol/mol or DCCT -HbA1C ≥ 7%)
  • Kras mutation in codon 12 or 13 (CRC patients only)
  • Known or suspected clinically active . Previously treated and stable brain metastases are allowable. Stable brain metastases are defined as no change on CT scan or MRI for minimum of two months AND no change in dose for a minimum of four weeks, unless change due to intercurrent infection or other acute event)
  • Any other significant medical or psychiatric condition that in the opinion of the investigator renders the patient inadequate for participation
  • History of severe to cetuximab
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    PX-866 (SCCHN)

    Phase 2 (Squamous Cell Carcinoma of the Head and Neck)

    Drug: PX-866 (SCCHN) · Drug: Cetuximab (SCCHN)

  • Active comparator
    Cetuximab (SCCHN)

    Phase 2 (Squamous Cell Carcinoma of the Head and Neck)

    Drug: Cetuximab (SCCHN)

  • Experimental
    PX-866 (CRC)

    Phase 2 (Colorectal Carcinoma)

    Drug: PX-866 (CRC) · Drug: Cetuximab (CRC)

  • Active comparator
    Cetuximab (CRC)

    Phase 2 (Colorectal Carcinoma)

    Drug: Cetuximab (CRC)

Interventions

  • PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.

  • Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.

    Also known as: Erbitux

  • PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.

  • Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.

    Also known as: Erbitux

07

What researchers measure

Primary outcomes

  1. The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.

    Time frame: 21 days

08

Study locations

40 sites
  • Birmingham Hematology and Oncology Assocs.
    Birmingham, Alabama 35223, United States
  • University of Alabama Birmingham
    Birmingham, Alabama 35249, United States
  • Southwest Cancer Care
    Escondido, California 92025, United States
  • Monterey Bay Oncology
    Monterey, California 93940, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Eastern Colorado Health Care System - (Denver VA)
    Denver, Colorado 80220, United States
  • George Washington University - Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Integrated Community Oncology Network
    Jacksonville, Florida 32256, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Pasco Pinellas Cancer Center
    New Port Richey, Florida 34652, United States
  • Peachtree Hematology-Oncology Consultants
    Atlanta, Georgia 30318, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Saint Louis Cancer Care LLP
    Bridgeton, Missouri 63044, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Northwest Cancer Specialists, P.C.
    Tualatin, Oregon 97062, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Mary Crowley Cancer Center
    Dallas, Texas 75230, United States
  • Texas Oncology - Baylor Charles A. Sammons
    Dallas, Texas 75246, United States
  • Texas Oncology - Fort Worth
    Fort Worth, Texas 76104, United States
  • Texas Oncology - Seton Williamson
    Round Rock, Texas 78665, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Oncology and Hematology Associates of Southwest Virginia
    Roanoke, Virginia 24014, United States
  • Columbia Basin Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Royal Victoria Regional Health Centre
    Barrie, Ontario L4M 6M2, Canada
  • London Regional Cancer Program
    London, Ontario N6A 4L6, Canada
  • Northeast Cancer Centre of Health Sciences North
    Sudbury, Ontario P3E 5J1, Canada
  • Thunder Bay Regional Health Sciences Centre
    Thunder Bay, Ontario P7B 6V4, Canada
  • Hôpital Charles-LeMoyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Cité de la Santé de Laval
    Laval, Quebec H7M 3L9, Canada
  • Maisonneuve-Rosemont Hospital Research Centre
    Montreal, Quebec H1T 2M4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Nov 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2010
First posted
Dec 3, 2010
Start
Dec 2010
Primary completionActual
Nov 2013
CompletionActual
Jan 2014
Results delay requested
Apr 30, 2015
Last update
May 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01252628
Responsible party
Sponsor
First posted
Dec 3, 2010
Start date
Dec 2010
Primary completion
Nov 2013
Completion
Jan 2014
Last update
May 16, 2018

Study contacts

Diana Hausman, MD
study director · Cascadian Therapeutics Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PX-866 · Cetuximab

Start the discussion